Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News TScan Therapeutics Inc TCRX

Healthcare Biotechnology
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual... see more

Recent & Breaking News (NDAQ:TCRX)

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

GlobeNewswire August 29, 2023

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 10, 2023

TScan Therapeutics Announces Transition of Chief Financial Officer

GlobeNewswire June 29, 2023

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

GlobeNewswire June 6, 2023

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting

GlobeNewswire June 1, 2023

TScan Therapeutics Announces Closing of Public Offering

GlobeNewswire June 1, 2023

TScan Therapeutics to Participate in the Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

TScan Therapeutics Announces Pricing of $140 Million Public Offering

GlobeNewswire May 26, 2023

TScan Therapeutics Announces Launch of Proposed Public Offering

GlobeNewswire May 25, 2023

TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors

GlobeNewswire May 24, 2023

TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting

GlobeNewswire May 17, 2023

TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 10, 2023

Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn's Disease

GlobeNewswire May 9, 2023

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting

GlobeNewswire May 2, 2023

TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors

GlobeNewswire April 10, 2023

TScan Therapeutics Announces CEO Transition

GlobeNewswire March 31, 2023

TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies

GlobeNewswire March 14, 2023

TScan Therapeutics to Participate in the Barclays Global Healthcare Conference

GlobeNewswire March 13, 2023

TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones

GlobeNewswire March 8, 2023

TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

GlobeNewswire March 1, 2023